<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83433</article-id><article-id pub-id-type="doi">10.7554/eLife.83433</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-292584"><name><surname>Watson</surname><given-names>James A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5524-0325</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292882"><name><surname>Commons</surname><given-names>Robert J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-124380"><name><surname>Tarning</surname><given-names>Joel</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4566-4030</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-97658"><name><surname>Simpson</surname><given-names>Julie A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2660-2013</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292883"><name><surname>Llanos Cuentas</surname><given-names>Alejandro</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-164119"><name><surname>Lacerda</surname><given-names>Marcus VG</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292884"><name><surname>Green</surname><given-names>Justin A</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-292885"><name><surname>Koh</surname><given-names>Gavin CKW</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-156811"><name><surname>Chu</surname><given-names>Cindy S</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35030"><name><surname>Nosten</surname><given-names>François H</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7951-0745</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-80033"><name><surname>Price</surname><given-names>Richard N</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2000-2874</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35005"><name><surname>Day</surname><given-names>Nicholas PJ</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2309-1171</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-235652"><name><surname>White</surname><given-names>Nicholas J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1897-1978</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution>Oxford University Clinical Research Unit</institution>, <addr-line><named-content content-type="city">Ho Chi Minh City</named-content></addr-line>, <country>Viet Nam</country></aff><aff id="aff2"><institution content-type="dept">Menzies School of Health Research</institution>, <institution>Charles Darwin University</institution>, <addr-line><named-content content-type="city">Darwin</named-content></addr-line>, <country>Australia</country></aff><aff id="aff3"><institution content-type="dept">Mahidol-Oxford Tropical Medicine Research Unit</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff4"><institution content-type="dept">Melbourne School of Population and Global Health</institution>, <institution>University of Melbourne</institution>, <addr-line><named-content content-type="city">Melbourne</named-content></addr-line>, <country>Australia</country></aff><aff id="aff5"><institution content-type="dept">Instituto de Medicina Tropical</institution>, <institution>Universidad Peruana Cayetano Heredia</institution>, <addr-line><named-content content-type="city">Lima</named-content></addr-line>, <country>Peru</country></aff><aff id="aff6"><institution>Tropical Medicine Foundation</institution>, <addr-line><named-content content-type="city">Manuas</named-content></addr-line>, <country>Brazil</country></aff><aff id="aff7"><institution>GlaxoSmithKline</institution>, <addr-line><named-content content-type="city">Brentford</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff8"><institution content-type="dept">Department of Infectious Diseases</institution>, <institution>Northwick Park Hospital</institution>, <addr-line><named-content content-type="city">Harrow</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff9"><institution content-type="dept">Shoklo Malaria Research Unit</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Mae Sot</named-content></addr-line>, <country>Thailand</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-21294"><name><surname>Krzych</surname><given-names>Urszula</given-names></name><role>Reviewing editor</role><aff><institution>Walter Reed Army Institute of Research</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>james@tropmedres.ac</email> (JW);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>nickw@tropmedres.ac</email> (NW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>6</day><month>12</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e83433</elocation-id><history><date date-type="received"><day>13</day><month>09</month><year>2022</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Watson et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Watson et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83433-v1.pdf"/><abstract><p>Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual data from 1,102 patients and 72 healthy volunteers studied in the pre-registration trials. We show that tafenoquine dose is the primary determinant of efficacy. Under an Emax model, we estimate the currently recommended 300mg dose in a 60kg adult (5mg/kg) results in 70% of the maximal obtainable hypnozoiticidal effect. Increasing the dose to 7.5mg/kg (i.e. 450mg) would result in 90% reduction in the risk of P. vivax recurrence. After adjustment for dose, the tafenoquine terminal elimination half-life, and day 7 methaemoglobin concentration, but not the parent compound exposure, were also associated with recurrence. These results suggest that the production of oxidative metabolites is central to tafenoquine's hypnozoiticidal efficacy. Clinical trials of higher tafenoquine doses are needed to characterise their efficacy, safety and tolerability.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>223253/Z/21/Z</award-id><principal-award-recipient><name><surname>Watson</surname><given-names>James A</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>093956/Z/10/C</award-id><principal-award-recipient><name><surname>White</surname><given-names>Nicholas J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Australian NHMRC</institution></institution-wrap></funding-source><award-id>1194702</award-id><principal-award-recipient><name><surname>Commons</surname><given-names>Robert J</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>200909</award-id><principal-award-recipient><name><surname>Price</surname><given-names>Richard N</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Australian NHMRC</institution></institution-wrap></funding-source><award-id>1196068</award-id><principal-award-recipient><name><surname>Simpson</surname><given-names>Julie A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Robert J Commons, has received an Emerging Leader Investigator Grant (1194702) from the Australian National Health &amp; Medical Research Council. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf3"><p>Joel Tarning, Joel Tarning has participated on the Novartis Malaria Advisory Council (payments made to their institution) and acts as an ASCPT Infectious Diseases steering committee member. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf4"><p>Justin A Green, was formerly an employee of GlaxoSmithKline who funded the pre-registration studies of tafenoquine. The author holds stock in GlaxoSmithKline. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf5"><p>Gavin CKW Koh, was formerly an employee of GlaxoSmithKline who funded the pre-registration studies of tafenoquine. The author holds stock in GlaxoSmithKline. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Anonymised individual patient data were obtained via ClinicalStudyDataRequest.com following approval of a research proposal from the Independent Review Panel.Re-use of existing, appropriately anonymised, human data does not require ethical approval under the Oxford Tropical Research Ethics Committee regulations (OxTREC).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The data used in this study can be accessed by submitting a research proposal via www.ClinicalStudyDataRequest.com using the following study codes: GSK-TAF112582; GSK-200951; GSK-TAF116564. Decisions to share data with independent researchers is made via an Independent Review Panel. All code used to process the data is available on https://github.com/jwatowatson/Tafenoquine-efficacy</p></sec></sec></back></article>